AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary
Top Cited Papers
- 1 July 2020
- journal article
- research article
- Published by Elsevier BV in Gastroenterology
- Vol. 159 (1), 350-357
- https://doi.org/10.1053/j.gastro.2020.04.012
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor AntagonistsClinical Gastroenterology and Hepatology, 2018
- Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving TofacitinibInflammatory Bowel Diseases, 2018
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release SyndromeThe Oncologist, 2018
- Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)Gut, 2017
- Approach to cytomegalovirus infections in patients with ulcerative colitisThe Korean Journal of Internal Medicine, 2017
- Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirusAntiviral Research, 2015
- Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including AlisporivirVirus Research, 2014
- Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506Virus Research, 2012
- Cyclosporin A inhibits the replication of diverse coronavirusesJournal of General Virology, 2011
- Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trialGut, 2011